Number of ever and never tumour necrosis factor-α inhibitor (TNFi)-treated patients in the DANBIO cohort and characteristics of patients with rheumatoid arthritis (RA) at first registration
| Ever TNFi* | Never TNFi | |
|---|---|---|
| Rheumatological diagnosis, N (%) | ||
| All | 10 294 (100) | 17 586 (100) |
| Female, N (%) | 6359 (62) | 11 806 (67) |
| RA | 5647 (55) | 11 974 (68) |
| Female, N (%) | 4207 (75) | 8595 (66) |
| PsA | 1603 (15) | 2286 (13) |
| Female, N (%) | 856 (53) | 1298 (57) |
| AS | 1728 (17) | 824 (5) |
| Female, N (%) | 493 (29) | 282 (34) |
| Other inflammatory arthritides | 1316 (13) | 2502 (14) |
| Female, N (%) | 803 (61) | 1631 (65) |
| Characteristics of RA patients at start of follow-up†‡ | ||
| Age, years | 55.0 (13) | 61.5 (14) |
| Age at rheumatological diagnosis, years | 45.4 (14) | 54.7 (27) |
| Year of registration, N (%) | ||
| 2000–2003 | 1016 (18) | 48 (0.4) |
| 2004–2007 | 2429 (43) | 3012 (25) |
| 2008–2011 | 2202 (39) | 8914 (74) |
| IgM RF positive, N (%) | 4030 (80) | 7699 (72) |
| Median (IQR) disease duration, years | 6.2 (1.7–14.1) | 2.8 (0.1–10.1) |
| Disease duration <2 years, N (%) | 1377 (27) | 4607 (38) |
| Tender joint count (0–28 scale) | 8.6 (7.3) | 4.4 (5.8) |
| Swollen joint count (0–28 scale) | 6.2 (5.5) | 2.9 (4.2) |
| HAQ | 1.2 (0.8) | 0.8 (0.7) |
| Median CRP (IQR), mg/L | 12 (5 to 29) | 7 (3 to 14) |
| DAS28-CRP | 4.8 (1.4) | 3.5 (1.4) |
| csDMARD treatment, N (%) | 4126 (73) | 8074 (67) |
*Patients who switched from no TNFi to TNFi treated (N=2609) contributed with person-years of observation in accordance with the time spent in each treatment group.
†Numbers are means (SD) unless otherwise indicated.
‡Missing values for ever versus never TNFi: age at diagnosis 11% vs 17%; IgM RF 11% vs 11%; tender joint count 9% vs 6%; swollen joint count 8% vs 6%; HAQ 20% vs 15%; CRP 8% vs 13%; DAS28-CRP 23% vs 25%; csDMARD treatment 0.3% vs 0%.
PsA, psoriatric arthritis; AS, ankylosing spondylitis; CRP, C- reactive protein; cs, conventional synthetic; DAS28-CRP, disease activity score using 28 joint count and CRP; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; IgM RF, immunoglobulin M rheumatoid factor; RA, rheumatoid arthritis.